Bensalah Karim, Zeltser Ilia, Tuncel Altug, Cadeddu Jeffrey, Lotan Yair
Department of Urology, University of Texas South-western Medical Center at Dallas, Dallas, Texas 75390-9110, USA.
BJU Int. 2008 Feb;101(4):467-71. doi: 10.1111/j.1464-410X.2007.07276.x. Epub 2007 Oct 8.
To compare the costs and morbidity of laparoscopic radiofrequency ablation (LRFA) and laparoscopic partial nephrectomy (LPN) for treating small localized renal tumours.
We retrospectively analysed the outcomes of 88 patients treated at our institution for a renal tumour either by LPN (50) or LRFA (38) between March 2000 and May 2006. Patients with multiple tumours, combined LRFA and LPN, and those who had other simultaneous surgical procedures were excluded. Clinical variables and outcomes were analysed for each patient. Direct cost data were available for 40 patients treated with LPN and 14 with LRFA. Continuous and categorical variables were compared using an independent t-test and chi-square test, respectively.
The tumour size was comparable in each group; patients in the LRFA group had more comorbidities (P = 0.01) and a higher overall mortality rate (P = 0.01) but no patient died from cancer. Operative duration, estimated blood loss and length of stay were significantly shorter in the LRFA group but there was no difference in complication rate. LRFA was less costly than LPN ($6103 vs $6808, P = 0.3) but not statistically significantly. The cost savings from the shorter operative duration and length of stay were reduced by the cost of probe. With a median follow-up of 20 months there was no difference in oncological outcome.
Patients undergoing LRFA tend to be older and have more comorbidities than those treated with LPN. The cost is minimally lower for LRFA, secondary to the added cost of the probe. LRFA might be a good alternative treatment in patients at higher risk of surgical complications, but LPN provides good results when done by an experienced surgeon.
比较腹腔镜射频消融术(LRFA)与腹腔镜部分肾切除术(LPN)治疗小的局限性肾肿瘤的成本和发病率。
我们回顾性分析了2000年3月至2006年5月期间在我院接受LPN(50例)或LRFA(38例)治疗肾肿瘤的88例患者的治疗结果。排除患有多发肿瘤、联合LRFA和LPN以及同时进行其他外科手术的患者。对每位患者的临床变量和结果进行分析。有40例行LPN治疗的患者和14例行LRFA治疗的患者可获得直接成本数据。连续变量和分类变量分别采用独立t检验和卡方检验进行比较。
每组患者的肿瘤大小相当;LRFA组患者的合并症更多(P = 0.01),总死亡率更高(P = 0.01),但无患者死于癌症。LRFA组的手术时间、估计失血量和住院时间明显更短,但并发症发生率无差异。LRFA的成本低于LPN(6103美元对6808美元,P = 0.3),但无统计学显著差异。手术时间和住院时间缩短带来的成本节省被探头成本抵消。中位随访20个月时,肿瘤学结果无差异。
与接受LPN治疗的患者相比,接受LRFA治疗的患者往往年龄更大,合并症更多。由于探头成本增加,LRFA的成本略低。对于手术并发症风险较高的患者,LRFA可能是一种很好的替代治疗方法,但由经验丰富的外科医生进行LPN时效果良好。